Table 2.

Summary of ER methylation and expression in Control and tamoxifen groups divided into women with persistent atypia or loss of atypia

ESR1 promoter methylationLow ER expression (IHC)
Women on tamoxifen (n = 17)
Persistent atypia (n = 8)07
Loss of atypia (n = 9)15
Control women (n = 16)
Persistent atypia (n = 15)411
Loss of atypia (n = 1)11
Whole cohort (n = 33)624
21%74%
  • NOTE: Summary of ER methylation and expression in control and tamoxifen groups divided into women with persistent atypia or loss of atypia. This table provides information for ESR1 promoter methylation and ER expression on 17 women who completed 12 mo of tamoxifen chemoprevention and 16 women who served as controls. Both the tamoxifen and control groups were divided into either persistent atypia (Masood ≥ 14) or loss of atypia (Masood < 14) at 12 mo. The data for the two groups combined is also represented (whole cohort).